Kaltura Inc vs Repligen Corporation Common Stock — how do they compare? Kaltura Inc trades at $1.38 (market cap $212.05M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 52.5× Kaltura Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kaltura Inc for 21 Days and Repligen Corporation Common Stock for 0 Days on average.
| KLTR | RGEN | |
|---|---|---|
Market Cap | $212.05M | $11.14B |
Volume | 264,699 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $1.89 | $194.57 |
52-Week Low | $1.08 | $102.87 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $224.26M | $11.02B |
Signals from Pluang's Aura AI — not financial advice
KLTR trades at $1.37, down 2.14% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages and oscillators. The company reported revenue of $180.85M in 2025, with a net loss of $12.07M, though losses have narrowed significantly from prior years. Recent news highlights include Gartner naming Kaltura a leader in AI for video platform services and a strategic partnership with Verimatrix for security.
The outlook remains speculative; while AI-driven growth and improving margins present upside potential, persistent losses, high valuation ratios, and negative cash flow pose substantial risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, but the stock's high volatility and weak profitability metrics warrant careful consideration.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →